In another study on HNSCC a neoadjuvant dose of either 40 Gy in five fractions or 24 Gy in three fractions was applied during one week selectively to the primary tumor in combination with the PD1-inhibitor Nivolumab prior to surgical treatment [5]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.